Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | MPL | P40238 | 10/20 | 0.40 |
| ▸ | ATR | Q13535 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13578319 | 0.95 | CHRNB2 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA4MPL | |
| Trifluoroacetic Acid SCHEMBL4327609 | 0.91 | MPL (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4MPL | |
| Trifluoroacetic Acid SCHEMBL4332928 | 0.90 | CHRNB2 (0.40) | CHRNB2CHRNB4CHRNA3CHRNA4MPL | |
| Trifluoroacetic Acid SCHEMBL4329922 | 0.90 | MPL (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4MPL | |
| Trifluoroacetic Acid SCHEMBL4319198 | 0.90 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4MPL | |
| Trifluoroacetic Acid SCHEMBL4319298 | 0.89 | CHRNB2 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA4MPL | |
| Trifluoroacetic Acid SCHEMBL4329693 | 0.89 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA4MPL | |
| Trifluoroacetic Acid SCHEMBL4339704 | 0.87 | CHRNB2 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4MPL | |
| Trifluoroacetic Acid SCHEMBL4324540 | 0.87 | L3MBTL1 (0.45) | CHRNB2CHRNB4CHRNA3CHRNA4MPL | |
| SCHEMBL13578330 | 0.87 | MPL (0.46) | CHRNB2CHRNB4CHRNA3CHRNA4MPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | CHRNB2 199/4885CHRNB4 188/4885CHRNA3 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.